Technical Analysis for 0EVI - Innate Pharma S.A.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.22 | -2.63% | -0.06 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.63% | |
MACD Bullish Signal Line Cross | Bullish | -2.63% | |
Narrow Range Bar | Range Contraction | -2.63% | |
Up 3 Days in a Row | Strength | -2.63% | |
Oversold Stochastic | Weakness | -2.63% | |
Narrow Range Bar | Range Contraction | -2.42% |
Get a Trading Sidekick!
Innate Pharma S.A. Description
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Classification
Keywords: Biotechnology Medicine Cancer Medical Specialties Clinical Medicine Monoclonal Antibodies Immunology Immune System Lung Cancer Immunotherapies
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.2957 |
52 Week Low | 1.9947 |
Average Volume | 2,691 |
200-Day Moving Average | 2.65 |
50-Day Moving Average | 2.61 |
20-Day Moving Average | 2.33 |
10-Day Moving Average | 2.24 |
Average True Range | 0.47 |
RSI (14) | 37.11 |
ADX | 36.87 |
+DI | 14.05 |
-DI | 5.85 |
Chandelier Exit (Long, 3 ATRs) | 1.63 |
Chandelier Exit (Short, 3 ATRs) | 3.58 |
Upper Bollinger Bands | 2.56 |
Lower Bollinger Band | 2.10 |
Percent B (%b) | 0.26 |
BandWidth | 19.67 |
MACD Line | -0.12 |
MACD Signal Line | -0.12 |
MACD Histogram | 0.0044 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.24 | ||||
Resistance 3 (R3) | 2.23 | 2.23 | 2.23 | ||
Resistance 2 (R2) | 2.23 | 2.22 | 2.23 | 2.23 | |
Resistance 1 (R1) | 2.22 | 2.22 | 2.23 | 2.23 | 2.23 |
Pivot Point | 2.22 | 2.22 | 2.22 | 2.22 | 2.22 |
Support 1 (S1) | 2.21 | 2.21 | 2.22 | 2.22 | 2.21 |
Support 2 (S2) | 2.21 | 2.21 | 2.21 | 2.21 | |
Support 3 (S3) | 2.20 | 2.21 | 2.21 | ||
Support 4 (S4) | 2.21 |